Impact of the pandemic on antimicrobial consumption patterns
SARS-CoV-2 probably changes the antibiotic consumption profile, and it is necessary to measure this difference. [...]our goal was to evaluate the impact of the pandemic on antimicrobial usage patterns comparing cohorts of SARS-CoV-2–positive and SARS-CoV-2–negative patients admitted in specific hosp...
Gespeichert in:
| Veröffentlicht in: | Infection control and hospital epidemiology 2021-09, Vol.42 (9), p.1170-1172 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1172 |
|---|---|
| container_issue | 9 |
| container_start_page | 1170 |
| container_title | Infection control and hospital epidemiology |
| container_volume | 42 |
| creator | da Silva, Cristófer Farias Deutschendorf, Caroline Nagel, Fabiano Márcio Dalmora, Camila Hubner dos Santos, Rodrigo Pires Lisboa, Thiago Costa |
| description | SARS-CoV-2 probably changes the antibiotic consumption profile, and it is necessary to measure this difference. [...]our goal was to evaluate the impact of the pandemic on antimicrobial usage patterns comparing cohorts of SARS-CoV-2–positive and SARS-CoV-2–negative patients admitted in specific hospital locations. The overall antibiotic use in the hospital during the study period was 73.0 DOT per 100 PD. The highest rate of antimicrobial use occurred in the COVID-19 emergency department (218.1 DOT per 100 PD), followed by the COVID-19 clinical ward (172.4 DOT per 100 PD), the COVID-19 ICU (134.3 DOT per 100 PD), the non–COVID-19 ICU (109.2 DOT per 100 PD), the non–COVID-19 emergency department (70.4 DOT per 100 PD), and the non–COVID-19 clinical ward (62.4 DOT per 100 PD) (Table 1). Antimicrobial Consumption Measured by Days of Therapy (DOT) per 100 Patient Days (PD) Antibiotic Intensive Care Units, DOT per 100 PD COVID-19 Non–COVID-19 COVID-19/Non–COVID-19, % P Value All antibiotics 134.4 109.2 123.1 |
| doi_str_mv | 10.1017/ice.2020.1227 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7542322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2445435592</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-c1a978b479edbfea4b957f14119d661bb3d01ce568a7b336a2e785cbac147c133</originalsourceid><addsrcrecordid>eNpdkc1LxDAQxYMo7rp69F7w4qVrvto0IIIsfiwseFHwFpI0dbO0SW1Swf_elF0EPc0M78djZh4AlwguEUTsxmqzxBCnCWN2BOaoKHheVoQegzmsOM8rTN5n4CyEHYSQcY5OwYxgXmLG-Bzcrrte6pj5Jotbk_XS1aazOvMuky7a1A5eWdlm2rswdn20SelljGZw4RycNLIN5uJQF-Dt8eF19ZxvXp7Wq_tNriktY66R5KxSlHFTq8ZIqnjBGkQR4nVZIqVIDZE2RVlJpggpJTasKrSSGlGmESELcLf37UfVmVobFwfZin6wnRy-hZdW_FWc3YoP_yVYQTHBOBlcHwwG_zmaEEVngzZtK53xYxCY0oKS9LkJvfqH7vw4uHSewAyzsoBVRROV76n0nhAG0_wug6CYchEpFzHlIqZcyA87zH_Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2727650884</pqid></control><display><type>article</type><title>Impact of the pandemic on antimicrobial consumption patterns</title><source>ProQuest Central</source><source>Cambridge University Press Journals Complete</source><creator>da Silva, Cristófer Farias ; Deutschendorf, Caroline ; Nagel, Fabiano Márcio ; Dalmora, Camila Hubner ; dos Santos, Rodrigo Pires ; Lisboa, Thiago Costa</creator><creatorcontrib>da Silva, Cristófer Farias ; Deutschendorf, Caroline ; Nagel, Fabiano Márcio ; Dalmora, Camila Hubner ; dos Santos, Rodrigo Pires ; Lisboa, Thiago Costa</creatorcontrib><description>SARS-CoV-2 probably changes the antibiotic consumption profile, and it is necessary to measure this difference. [...]our goal was to evaluate the impact of the pandemic on antimicrobial usage patterns comparing cohorts of SARS-CoV-2–positive and SARS-CoV-2–negative patients admitted in specific hospital locations. The overall antibiotic use in the hospital during the study period was 73.0 DOT per 100 PD. The highest rate of antimicrobial use occurred in the COVID-19 emergency department (218.1 DOT per 100 PD), followed by the COVID-19 clinical ward (172.4 DOT per 100 PD), the COVID-19 ICU (134.3 DOT per 100 PD), the non–COVID-19 ICU (109.2 DOT per 100 PD), the non–COVID-19 emergency department (70.4 DOT per 100 PD), and the non–COVID-19 clinical ward (62.4 DOT per 100 PD) (Table 1). Antimicrobial Consumption Measured by Days of Therapy (DOT) per 100 Patient Days (PD) Antibiotic Intensive Care Units, DOT per 100 PD COVID-19 Non–COVID-19 COVID-19/Non–COVID-19, % P Value All antibiotics 134.4 109.2 123.1 <.001 Amoxicillin/clavulanate 22.4 5.0 448.0 Azithromycin 21.3 4.8 443.8 Cefepime 22.8 12.5 182.4 Meropenem 11.7 23.8 49.2 Piperacillin/tazobactam 3.3 9.1 36.3 Vancomycin 5.6 18.8 29.8 Emergency department All antibiotics 218.1 70.4 309.8 <.001 Amoxicillin/clavulanate 59.7 17.5 341.1 Azithromycin 71.5 2.8 2553.6 Cefepime 28.5 11.4 250.0 Ceftazidime 3.5 2.9 120.7 Cefuroxime 16.0 10.1 158.4 Metronidazole 3.5 3.6 97.2 Piperacillin/tazobactam 5.6 3.4 164.7 Clinical ward All antibiotics 172.4 62.4 276.3 <.001 Amoxicillin/clavulanate 41.1 4.8 856.3 Azithromycin 43.8 2.1 2,085.7 Cefepime 17.0 7.9 215.2 Cefuroxime 5.4 2.5 216.0 Meropenem 6.2 8.6 72.1 Piperacillin/tazobactam 7.9 6.6 119.7 Sulfamethoxazole and trimethoprim 3.0 4.0 75.0 Vancomycin 3.7 3.6 102.8 Also, β-lactams and macrolides were used at a higher rate in COVID-19 clusters.</description><identifier>ISSN: 0899-823X</identifier><identifier>EISSN: 1559-6834</identifier><identifier>DOI: 10.1017/ice.2020.1227</identifier><identifier>PMID: 32962779</identifier><language>eng</language><publisher>Cambridge: Cambridge University Press</publisher><subject>Antibiotics ; Antimicrobial agents ; Cluster analysis ; Consumption patterns ; Coronaviruses ; COVID-19 ; Disease transmission ; Drug resistance ; Emergency medical care ; Hospitals ; Intensive care ; Letter to the Editor ; Nursing ; Pandemics ; Patients ; Prescription drugs ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Infection control and hospital epidemiology, 2021-09, Vol.42 (9), p.1170-1172</ispartof><rights>2020 by The Society for Healthcare Epidemiology of America. All rights reserved. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Society for Healthcare Epidemiology of America 2020 2020 The Society for Healthcare Epidemiology of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-c1a978b479edbfea4b957f14119d661bb3d01ce568a7b336a2e785cbac147c133</citedby><cites>FETCH-LOGICAL-c446t-c1a978b479edbfea4b957f14119d661bb3d01ce568a7b336a2e785cbac147c133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2727650884/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2727650884?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,776,780,881,21367,27901,27902,33721,33722,43781,74045</link.rule.ids></links><search><creatorcontrib>da Silva, Cristófer Farias</creatorcontrib><creatorcontrib>Deutschendorf, Caroline</creatorcontrib><creatorcontrib>Nagel, Fabiano Márcio</creatorcontrib><creatorcontrib>Dalmora, Camila Hubner</creatorcontrib><creatorcontrib>dos Santos, Rodrigo Pires</creatorcontrib><creatorcontrib>Lisboa, Thiago Costa</creatorcontrib><title>Impact of the pandemic on antimicrobial consumption patterns</title><title>Infection control and hospital epidemiology</title><description>SARS-CoV-2 probably changes the antibiotic consumption profile, and it is necessary to measure this difference. [...]our goal was to evaluate the impact of the pandemic on antimicrobial usage patterns comparing cohorts of SARS-CoV-2–positive and SARS-CoV-2–negative patients admitted in specific hospital locations. The overall antibiotic use in the hospital during the study period was 73.0 DOT per 100 PD. The highest rate of antimicrobial use occurred in the COVID-19 emergency department (218.1 DOT per 100 PD), followed by the COVID-19 clinical ward (172.4 DOT per 100 PD), the COVID-19 ICU (134.3 DOT per 100 PD), the non–COVID-19 ICU (109.2 DOT per 100 PD), the non–COVID-19 emergency department (70.4 DOT per 100 PD), and the non–COVID-19 clinical ward (62.4 DOT per 100 PD) (Table 1). Antimicrobial Consumption Measured by Days of Therapy (DOT) per 100 Patient Days (PD) Antibiotic Intensive Care Units, DOT per 100 PD COVID-19 Non–COVID-19 COVID-19/Non–COVID-19, % P Value All antibiotics 134.4 109.2 123.1 <.001 Amoxicillin/clavulanate 22.4 5.0 448.0 Azithromycin 21.3 4.8 443.8 Cefepime 22.8 12.5 182.4 Meropenem 11.7 23.8 49.2 Piperacillin/tazobactam 3.3 9.1 36.3 Vancomycin 5.6 18.8 29.8 Emergency department All antibiotics 218.1 70.4 309.8 <.001 Amoxicillin/clavulanate 59.7 17.5 341.1 Azithromycin 71.5 2.8 2553.6 Cefepime 28.5 11.4 250.0 Ceftazidime 3.5 2.9 120.7 Cefuroxime 16.0 10.1 158.4 Metronidazole 3.5 3.6 97.2 Piperacillin/tazobactam 5.6 3.4 164.7 Clinical ward All antibiotics 172.4 62.4 276.3 <.001 Amoxicillin/clavulanate 41.1 4.8 856.3 Azithromycin 43.8 2.1 2,085.7 Cefepime 17.0 7.9 215.2 Cefuroxime 5.4 2.5 216.0 Meropenem 6.2 8.6 72.1 Piperacillin/tazobactam 7.9 6.6 119.7 Sulfamethoxazole and trimethoprim 3.0 4.0 75.0 Vancomycin 3.7 3.6 102.8 Also, β-lactams and macrolides were used at a higher rate in COVID-19 clusters.</description><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Cluster analysis</subject><subject>Consumption patterns</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Disease transmission</subject><subject>Drug resistance</subject><subject>Emergency medical care</subject><subject>Hospitals</subject><subject>Intensive care</subject><subject>Letter to the Editor</subject><subject>Nursing</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Prescription drugs</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>0899-823X</issn><issn>1559-6834</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkc1LxDAQxYMo7rp69F7w4qVrvto0IIIsfiwseFHwFpI0dbO0SW1Swf_elF0EPc0M78djZh4AlwguEUTsxmqzxBCnCWN2BOaoKHheVoQegzmsOM8rTN5n4CyEHYSQcY5OwYxgXmLG-Bzcrrte6pj5Jotbk_XS1aazOvMuky7a1A5eWdlm2rswdn20SelljGZw4RycNLIN5uJQF-Dt8eF19ZxvXp7Wq_tNriktY66R5KxSlHFTq8ZIqnjBGkQR4nVZIqVIDZE2RVlJpggpJTasKrSSGlGmESELcLf37UfVmVobFwfZin6wnRy-hZdW_FWc3YoP_yVYQTHBOBlcHwwG_zmaEEVngzZtK53xYxCY0oKS9LkJvfqH7vw4uHSewAyzsoBVRROV76n0nhAG0_wug6CYchEpFzHlIqZcyA87zH_Q</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>da Silva, Cristófer Farias</creator><creator>Deutschendorf, Caroline</creator><creator>Nagel, Fabiano Márcio</creator><creator>Dalmora, Camila Hubner</creator><creator>dos Santos, Rodrigo Pires</creator><creator>Lisboa, Thiago Costa</creator><general>Cambridge University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20210901</creationdate><title>Impact of the pandemic on antimicrobial consumption patterns</title><author>da Silva, Cristófer Farias ; Deutschendorf, Caroline ; Nagel, Fabiano Márcio ; Dalmora, Camila Hubner ; dos Santos, Rodrigo Pires ; Lisboa, Thiago Costa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-c1a978b479edbfea4b957f14119d661bb3d01ce568a7b336a2e785cbac147c133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Cluster analysis</topic><topic>Consumption patterns</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Disease transmission</topic><topic>Drug resistance</topic><topic>Emergency medical care</topic><topic>Hospitals</topic><topic>Intensive care</topic><topic>Letter to the Editor</topic><topic>Nursing</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Prescription drugs</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>da Silva, Cristófer Farias</creatorcontrib><creatorcontrib>Deutschendorf, Caroline</creatorcontrib><creatorcontrib>Nagel, Fabiano Márcio</creatorcontrib><creatorcontrib>Dalmora, Camila Hubner</creatorcontrib><creatorcontrib>dos Santos, Rodrigo Pires</creatorcontrib><creatorcontrib>Lisboa, Thiago Costa</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Infection control and hospital epidemiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>da Silva, Cristófer Farias</au><au>Deutschendorf, Caroline</au><au>Nagel, Fabiano Márcio</au><au>Dalmora, Camila Hubner</au><au>dos Santos, Rodrigo Pires</au><au>Lisboa, Thiago Costa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of the pandemic on antimicrobial consumption patterns</atitle><jtitle>Infection control and hospital epidemiology</jtitle><date>2021-09-01</date><risdate>2021</risdate><volume>42</volume><issue>9</issue><spage>1170</spage><epage>1172</epage><pages>1170-1172</pages><issn>0899-823X</issn><eissn>1559-6834</eissn><abstract>SARS-CoV-2 probably changes the antibiotic consumption profile, and it is necessary to measure this difference. [...]our goal was to evaluate the impact of the pandemic on antimicrobial usage patterns comparing cohorts of SARS-CoV-2–positive and SARS-CoV-2–negative patients admitted in specific hospital locations. The overall antibiotic use in the hospital during the study period was 73.0 DOT per 100 PD. The highest rate of antimicrobial use occurred in the COVID-19 emergency department (218.1 DOT per 100 PD), followed by the COVID-19 clinical ward (172.4 DOT per 100 PD), the COVID-19 ICU (134.3 DOT per 100 PD), the non–COVID-19 ICU (109.2 DOT per 100 PD), the non–COVID-19 emergency department (70.4 DOT per 100 PD), and the non–COVID-19 clinical ward (62.4 DOT per 100 PD) (Table 1). Antimicrobial Consumption Measured by Days of Therapy (DOT) per 100 Patient Days (PD) Antibiotic Intensive Care Units, DOT per 100 PD COVID-19 Non–COVID-19 COVID-19/Non–COVID-19, % P Value All antibiotics 134.4 109.2 123.1 <.001 Amoxicillin/clavulanate 22.4 5.0 448.0 Azithromycin 21.3 4.8 443.8 Cefepime 22.8 12.5 182.4 Meropenem 11.7 23.8 49.2 Piperacillin/tazobactam 3.3 9.1 36.3 Vancomycin 5.6 18.8 29.8 Emergency department All antibiotics 218.1 70.4 309.8 <.001 Amoxicillin/clavulanate 59.7 17.5 341.1 Azithromycin 71.5 2.8 2553.6 Cefepime 28.5 11.4 250.0 Ceftazidime 3.5 2.9 120.7 Cefuroxime 16.0 10.1 158.4 Metronidazole 3.5 3.6 97.2 Piperacillin/tazobactam 5.6 3.4 164.7 Clinical ward All antibiotics 172.4 62.4 276.3 <.001 Amoxicillin/clavulanate 41.1 4.8 856.3 Azithromycin 43.8 2.1 2,085.7 Cefepime 17.0 7.9 215.2 Cefuroxime 5.4 2.5 216.0 Meropenem 6.2 8.6 72.1 Piperacillin/tazobactam 7.9 6.6 119.7 Sulfamethoxazole and trimethoprim 3.0 4.0 75.0 Vancomycin 3.7 3.6 102.8 Also, β-lactams and macrolides were used at a higher rate in COVID-19 clusters.</abstract><cop>Cambridge</cop><pub>Cambridge University Press</pub><pmid>32962779</pmid><doi>10.1017/ice.2020.1227</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0899-823X |
| ispartof | Infection control and hospital epidemiology, 2021-09, Vol.42 (9), p.1170-1172 |
| issn | 0899-823X 1559-6834 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7542322 |
| source | ProQuest Central; Cambridge University Press Journals Complete |
| subjects | Antibiotics Antimicrobial agents Cluster analysis Consumption patterns Coronaviruses COVID-19 Disease transmission Drug resistance Emergency medical care Hospitals Intensive care Letter to the Editor Nursing Pandemics Patients Prescription drugs Severe acute respiratory syndrome coronavirus 2 |
| title | Impact of the pandemic on antimicrobial consumption patterns |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T02%3A02%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20the%20pandemic%20on%20antimicrobial%20consumption%20patterns&rft.jtitle=Infection%20control%20and%20hospital%20epidemiology&rft.au=da%20Silva,%20Crist%C3%B3fer%20Farias&rft.date=2021-09-01&rft.volume=42&rft.issue=9&rft.spage=1170&rft.epage=1172&rft.pages=1170-1172&rft.issn=0899-823X&rft.eissn=1559-6834&rft_id=info:doi/10.1017/ice.2020.1227&rft_dat=%3Cproquest_pubme%3E2445435592%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2727650884&rft_id=info:pmid/32962779&rfr_iscdi=true |